{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:17:15Z","timestamp":1790788635339,"version":"4.1.0"},"reference-count":124,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA100707, P01CA155258, RO1 CA 207237"],"award-info":[{"award-number":["P50 CA100707, P01CA155258, RO1 CA 207237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy. Novel immunotherapies will significantly improve patient outcome via simultaneously targeting malignant plasma cell (PC) and reversing immunocompromised bone marrow (BM) microenvironment. B-cell maturation antigen (BCMA), selectively expressed in PCs and a key receptor for A proliferation-inducing ligand (APRIL), is highly expressed in MM cells from patients at all stages. The APRIL\/BCMA signal cascades promote the survival and drug resistance of MM cells and further modulate immunosuppressive BM milieu. Impressively, anti-BCMA immunotherapeutic reagents, including chimeric antigen receptor (CAR), antibody-drug conjugate (ADC) and bispecific T cell engager (BiTE) have all shown high response rates in their first clinical trials in relapse and refractory patients with very limited treatment options. These results rapidly inspired numerous development of next-generation anti-BCMA biotherapeutics, i.e., bispecific molecule, bispecific or trispecific antibodies, a novel form of CAR T\/NK cells and T Cell Antigen Coupler (TAC) receptors, antibody-coupled T cell receptor (ACTR) as well as a cancer vaccine. We here highlight seminal preclinical and clinical studies on novel BCMA-based immunotherapies as effective monotherapy and discuss their potential in combination with current anti-MM and novel checkpoint drugs in earlier disease stages to further achieve durable responses in patients.<\/jats:p>","DOI":"10.3390\/cancers12061473","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T06:34:16Z","timestamp":1591684456000},"page":"1473","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma"],"prefix":"10.3390","volume":"12","author":[{"given":"Shih-Feng","family":"Cho","sequence":"first","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"},{"name":"Division of Hematology &amp; Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan"},{"name":"Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lin","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Xing","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Li","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-3003","authenticated-orcid":false,"given":"Tengteng","family":"Yu","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C","family":"Anderson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2016-06-719856","article-title":"A new era of immune therapy in multiple myeloma","volume":"128","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"Laabi","year":"1992","journal-title":"EMBO J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: A tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1158\/1078-0432.CCR-07-1758","article-title":"Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications","volume":"13","author":"Mahtouk","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-01-332940","article-title":"Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow","volume":"118","author":"Matthes","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: Therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/leu.2015.68","article-title":"Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow","volume":"29","author":"Matthes","year":"2015","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: Role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: Therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","article-title":"A molecular compendium of genes expressed in multiple myeloma","volume":"100","author":"Claudio","year":"2002","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-05-1657","article-title":"Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"Gamma-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Smith, E.L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T.J., Ng, K.Y., Ghoddusi, M., Purdon, T.J., and Wang, X. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med., 11.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2019-126145","article-title":"Optimal dual-targeted CAR construct simultaneously targeting Bcma and GPRC5D prevents Bcma-escape driven relapse in multiple myeloma","volume":"134","author":"Staehr","year":"2019","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood-2018-99-111729","article-title":"A phase 1 study of two investigational agents, ACTR087, an autologous T cell product expressing an antibody-coupled T cell receptor, in combination with SEA-BCMA, a novel non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma","volume":"132","author":"Benson","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"Raje","year":"2020","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","article-title":"Durable remission achieved from Bcma-directed CAR-T therapy against relapsed or refractory multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2019.37.15_suppl.2535","article-title":"The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain","volume":"37","author":"Han","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","article-title":"Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: Initial safety and efficacy report from a clinical pilot study","volume":"132","author":"Shi","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood-2019-129740","article-title":"Sequential CD19- and Bcma-specific chimeric antigen receptor T cell treatment for RRMM: Report from a single center study","volume":"134","author":"Yan","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2019-131515","article-title":"Combination anti-Bcma and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma","volume":"134","author":"Garfall","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/blood-2019-126104","article-title":"Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed\/refractory multiple myeloma","volume":"134","author":"Jie","year":"2019","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2019-128468","article-title":"Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2019-130008","article-title":"Updated phase 1 results of a first-in-human open-label study of Lcar-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (Bcma)","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: Final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"ref_83","first-page":"506","article-title":"Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: Initial safety and efficacy report from a clinical pilot study","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer, J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): Interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Raje","year":"2019","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Xing, L., Lin, L., Yu, T., Li, Y., Cho, S.F., Liu, J., Wen, K., Hsieh, P.A., Kinneer, K., and Munshi, N. (2020). A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia.","DOI":"10.1038\/s41375-020-0745-9"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood-2018-99-118412","article-title":"HDP101, a novel B-cell maturation antigen (BCMA)-targeted antibody conjugated to \u03b1-amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p","volume":"132","author":"Singh","year":"2018","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1538-7445.AM2017-77","article-title":"Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate","volume":"77","author":"Hechler","year":"2017","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1073\/pnas.0811427106","article-title":"Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10","volume":"106","author":"Klein","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2019-128528","article-title":"AMG 701 potently induces anti-multiple myeloma (MM) functions of T cells and IMiDs further enhance its efficacy to prevent MM relapse in vivo","volume":"134","author":"Cho","year":"2019","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2018.36.15_suppl.8034","article-title":"Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma","volume":"36","author":"Buelow","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: Overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","article-title":"Preclinical and nonclinical characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood-2019-121595","article-title":"Preclinical evaluation of CD8+ anti-Bcma mRNA CAR T-cells for the control of human multiple myeloma","volume":"34","author":"Lin","year":"2019","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2019.37.15_suppl.8012","article-title":"Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma","volume":"37","author":"Bensinger","year":"2019","journal-title":"J. Clin. Oncol"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41408-017-0028-5","article-title":"MRD in multiple myeloma: More questions than answers?","volume":"7","author":"Moreau","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"EHA SWG on \u2018Aging and Hematology. Elderly patients with multiple myeloma: Towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Stoiber, S., Cadilha, B.L., Benmebarek, M.R., Lesch, S., Endres, S., and Kobold, S. (2019). Limitations in the design of chimeric antigen receptors for cancer therapy. Cells, 8.","DOI":"10.3390\/cells8050472"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2019-129582","article-title":"Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase","volume":"134","author":"Green","year":"2019","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1473\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:51Z","timestamp":1760175351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":124,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061473"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061473","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}